Boston Trust Walden’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$114M Sell
1,035,813
-47,249
-4% -$4.56M 0.92% 17
2026
Q2
$84.8M Buy
1,083,062
+403,499
+59% +$27.5M 0.65% 47
2026
Q1
$43.9M Sell
679,563
-102,272
-13% -$7.21M 0.36% 100
2025
Q4
$52.6M Sell
781,835
-52,058
-6% -$3.5M 0.4% 95
2025
Q3
$61.2M Sell
833,893
-11,353
-1% -$754K 0.45% 83
2025
Q2
$44M Sell
845,246
-21,626
-2% -$1.23M 0.31% 129
2025
Q1
$55.3M Sell
866,872
-7,209
-0.8% -$419K 0.4% 95
2024
Q4
$41.8M Buy
874,081
+191,465
+28% +$9.8M 0.29% 139
2024
Q3
$39.1M Buy
682,616
+239,321
+54% +$13.7M 0.27% 143
2024
Q2
$23.2M Buy
+443,295
New +$19.4M 0.17% 159

Other funds holding HALO

Boston Trust Walden's HALO Position: Q3 2026 in Review

Boston Trust Walden reduced its Halozyme (HALO) stake by 4.4% in Q3 2026, selling an estimated $4.56M and leaving 1,035,813 shares worth $114M. The position accounts for 0.92% of the portfolio, ranked #17.

Boston Trust Walden first reported a position in HALO in Q2 2024 and has held it in 10 quarters since. 772 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Boston Trust Walden held 1,035,813 shares of Halozyme worth $114M as of Q3 2026.
  • Boston Trust Walden sold 47,249 Halozyme shares in Q3 2026, an estimated $4.56M.
  • Halozyme made up 0.92% of Boston Trust Walden's portfolio in Q3 2026, its #17 holding.
  • Boston Trust Walden first reported a position in Halozyme in Q2 2024 and has held it in 10 quarters since.
  • 772 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Boston Trust Walden's 13F filing for Q3 2026, filed 30 Oct 2026.